Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 12/20 | 0.75 |
| ▸ | CHRNA4 known ✓ | P43681 | 12/20 | 0.75 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.75 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.75 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.75 |
| ▸ | CHRNG | P07510 | 2/20 | 0.75 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.75 |
| ▸ | CHRND | Q07001 | 2/20 | 0.75 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.75 |
| ▸ | HTR3A | P46098 | 1/20 | 0.75 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL225687 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL14003841 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL137144 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29363551 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 0.87 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553851 | 0.85 | CHRNB2 (0.96) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413921 | 0.85 | CHRNB4 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.84 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL20553911 | 0.84 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200276113-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC BIO, INC. (KR) | 2020-09-03 | — | — | US | claimed |
| EP-3400964-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC Bio, Inc. (KR) | 2018-11-14 | — | — | EP | claimed |
| WO-2024069649-A1 | COMPOSITIONS WITH REDUCED NITROSAMINE IMPURITIES | INVENTIA HEALTHCARE LIMITED (IN) | 2024-04-04 | — | — | WO | disclosed |
| US-11266658-B2 | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration | CTC BIO, INC. (KR) | 2022-03-08 | — | — | US | disclosed |
| US-20200276113-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC BIO, INC. (KR) | 2020-09-03 | — | — | US | disclosed |
| US-20200061078-A1 | PREPARATION, COMPRISING INCLUSION COMPLEX OF VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR ORAL ADMINISTRATION | CTC BIO, INC. (KR) | 2020-02-27 | — | — | US | disclosed |
| EP-3400964-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CTC Bio, Inc. (KR) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266658-B2 | Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration | TAS2R7, CACNG7, CYP3A7 | CHRNB2 292/4885CHRNA4 283/4885CHRNB4 351/4885 |
| US-20200276113-A1 | TASTE-MASKED AND ORALLY ADMINISTERED PHARMACEUTICAL PREPARATION CONTAINING VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TAS2R7, TAS2R5, TAS2R10 | CHRNB2 156/4885CHRNA4 138/4885CHRNB4 220/4885 |
| US-20200061078-A1 | PREPARATION, COMPRISING INCLUSION COMPLEX OF VARENICLINE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR ORAL ADMINISTRATION | TAS2R7, CACNG7, CYP3A7 | CHRNB2 292/4885CHRNA4 283/4885CHRNB4 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.